Medexus Pharmaceuticals Inc. (TSE:MDP - Get Free Report) rose 4.4% during trading on Thursday . The company traded as high as C$2.92 and last traded at C$2.85. Approximately 31,566 shares traded hands during mid-day trading, a decline of 53% from the average daily volume of 67,285 shares. The stock had previously closed at C$2.73.
Analysts Set New Price Targets
Separately, Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a "strong-buy" rating in a research note on Monday, August 11th. Four equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of C$4.57.
Read Our Latest Research Report on MDP
Medexus Pharmaceuticals Stock Up 4.4%
The firm has a market cap of C$91.94 million, a PE ratio of 142.50 and a beta of 1.60. The company's fifty day moving average price is C$2.91 and its two-hundred day moving average price is C$2.82.
Medexus Pharmaceuticals Company Profile
(
Get Free Report)
Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
